The latest from Mexican pharma, including the distribution agreement between Dow and Azelis, Neuraxpharm’s new LatAm subsidiaries in Mexico and Brazil; Landsteiner Scientific’s restructure, and Merck’s plant expansion in Naucalpan.
Dow and Azelis México, distribution partners for the pharmaceutical market (T21, in Spanish)
Dow announced its alliance with Azelis, a service provider in the chemical industry, for distribution in the pharmaceutical market, in which they will give their customers access to Dow’s active pharmaceutical ingredients (API) and excipients from June 1 past.
Through this collaboration, Dow, together with Azelis, seeks to strengthen its presence in the pharmaceutical industry in Mexico, according to Víctor Pérez, Commercial Director of Industrial Solutions for Dow.
European pharmaceutical company Neuraxpharm expands into Latin America with two new subsidiaries in Brazil and Mexico (America Economia, in Spanish)
The Neuraxpharm Group, a laboratory of pharmaceutical products for disorders that affect the central nervous system (CNS), has announced the creation of two new subsidiaries in Brazil and Mexico, two of the largest pharmaceutical markets in Latin America, thus taking the first steps its expansion outside of Europe.
Indian vaccine majors in talk with Mexico to bolster healthcare (The Pharma Letter)
The Serum Institute of India and Bharat Biotech are in talks with the Mexican government for manufacturing vaccines in a deal that will help the two Indian pharmaceutical companies expand their presence in Mexico and the Latin American market.
As part of its efforts to boost its pharmaceutical industry and reduce reliance on imports for critical drugs and vaccines, Mexico is seeking technology collaborations and investments from Indian drug makers.
Landsteiner, restructuring, against the current (El Economista, in Spanish)
An agreement to restructure the liabilities of the pharmaceutical company Landsteiner Scientific directed by Miguel Granados was formalized. The agreement was reached by virtue of the Mercantile Contest to which the company was subjected, with 91.70 percent approval votes. The debt restructuring is with Bancomext and a group of private banks. With Bancomext, the restructuring is for 850 million pesos for a term of 15 years and with an initial payment of 12.5 percent of the original amount.
Merck will expand its plant in the State of Mexico (Immobiliare, in Spanish)
Merck, a benchmark for the Mexican pharmaceutical industry, is announcing a new investment in Edoméx for 20 million euros, aimed at expanding its plant in Naucalpan.
The Head of the local Executive recognized that the investment has had a positive impact on the economic growth of the entity, as well as on the development of state production chains and the opening of technical and quality job opportunities for the population.
Ocugen gains rights to market Covid-19 vaccine in Mexico (Pharmaceutical Technology)
Ocugen and Bharat Biotech have signed an amendment to their co-development, supply and commercialisation agreement for expanding the former’s exclusive territory to include marketing of their Covid-19 vaccine, Covaxin (BBV152), in Mexico. With the latest development, Ocugen will have complete commercialisation rights to Covaxin in North America.
